ANGLE plc
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 sys… Read more
ANGLE plc - Asset Resilience Ratio
ANGLE plc (ANPCF) has an Asset Resilience Ratio of 33.24% as of April 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2020)
This chart shows how ANGLE plc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down ANGLE plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $11.55 Million | 33.24% |
| Total Liquid Assets | $11.55 Million | 33.24% |
Asset Resilience Insights
- Very High Liquidity: ANGLE plc maintains exceptional liquid asset reserves at 33.24% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ANGLE plc Industry Peers by Asset Resilience Ratio
Compare ANGLE plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for ANGLE plc (2003–2020)
The table below shows the annual Asset Resilience Ratio data for ANGLE plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 42.35% | $16.54 Million | $39.05 Million | +21.08pp |
| 2012-12-31 | 21.27% | $1.60 Million | $7.52 Million | +12.11pp |
| 2008-12-31 | 9.16% | $499.00K | $5.45 Million | -2.19pp |
| 2007-12-31 | 11.35% | $1.04 Million | $9.18 Million | -12.05pp |
| 2006-12-31 | 23.40% | $1.81 Million | $7.74 Million | -6.79pp |
| 2005-12-31 | 30.20% | $4.87 Million | $16.12 Million | 0.00pp |
| 2004-12-31 | 30.20% | $4.87 Million | $16.12 Million | +10.31pp |
| 2003-12-31 | 19.89% | $2.40 Million | $12.06 Million | -- |